drugset / Trial / NCT01822977

The Impact of Proton Pump Inhibitors on the Fecal Microbiome

NCT01822977

Phase 1 Completed 15 enrolled Mayo Clinic
NaSingle-groupOpen-label

Summary

The investigators hypothesis is that daily use of a proton pump inhibitor (PPI) is associated with significant alterations in the healthy fecal microbiome that are similar to those seen in persons with an initial episode of clostridium difficile infection (CDI).

Timeline

Start
2013-03
Primary completion
2013-12
Completion
2013-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Omeprazole Other / unclassified 20 mg